More Benefits for Checkpoint Inhibitors in NSCLC.
At the European Cancer Congress held in September 2015 in Vienna, Austria, three research teams presented evidence showing that the checkpoint inhibitors nivolumab and atezolizumab are effective as second-line therapies in certain patients with non-small cell lung cancer.
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor